Release date: 2024-08-07 17:12:12 Article From: Lucius Laos Recommended: 118
Capmatinib acts as a targeted therapy to stop the growth and spread of cancer cells by inhibiting MET tyrosine kinase activity. Usually, this medication is for those who do not respond to other therapies or are no longer effective.
Capmatinib brings new therapeutic hope to patients with specific non-small cell lung cancer (NSCLC) who carry exon 14 skipping mutations in the MET gene. Mutations in METex14 cause abnormally active MET proteins, which promote the growth and spread of cancer cells. As a MET inhibitor, capmatinib inhibits the proliferation and spread of cancer cells by precisely intervening in abnormal signaling pathways.
By directly targeting specific gene mutations in tumor cells, capmatinib helps to better control tumor progression, prolong patient survival, and improve quality of life. In these patients, which respond poorly to conventional chemotherapy or immunotherapy, capmatinib offers a more effective treatment option. In clinical practice, doctors prioritize the inclusion of capmatinib in the treatment regimen after genetic testing confirms the presence of a METex14 mutation.
Before purchasing and using the drug, patients should be aware of the drug interactions associated with capmatinib, which are organized as follows:
When capmatinib is used, strong inhibitors of CYP3A may increase the concentration of the drug, leading to serious adverse reactions. Concomitant use of these drugs, including but not limited to itraconazole, ketoconazole, voriconazole, atazanavir, ritonavir, clarithromycin, and grapefruit, should be avoided.
CYP3A inducers may reduce the efficacy of capmatinib, leading to reduced anti-tumor activity. Concomitant use of common inducers should be avoided, including antituberculous drugs rifampicin, rifapentine, phenytoin, carbamazepine, barbiturates, and St. John's wort.
[Warm Tips] The use of any medication is accompanied by certain risks and potential side effects, if patients experience discomfort during the process of taking the drug, please seek medical attention in time for professional help.
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:2012024-09-07
On November 14, 2024, the Committee for Medicinal Products for Human Use (CHMP) of the European Medi···【more】
Recommended:1582025-13-01
Recent advancements have reaffirmed the significance of liquid biopsy in the management of advanced ···【more】
Recommended:1562025-06-01
FDA Approves First Generic Version of Victoza (liraglutide injection)The U.S. Food and Drug Administ···【more】
Recommended:1712024-30-12
The new indication involves the treatment of adult patients with locally advanced, unresectable non-···【more】
Recommended:1612024-24-12
he U.S. Food and Drug Administration (FDA) has approved Crenessity (crinecerfont) for use in combina···【more】
Recommended:1462024-17-12
In the phase Ib/II multicenter pivotal FELIX study, the autologous 41BB-ζ anti-CD19 chimeric antigen···【more】
Recommended:1052024-13-12
On 25 July 2024, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHM···【more】
Recommended:2482024-26-08
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: